About NGN Capital
NGN Capital is a venture capital firm founded in 2003. It is primarily based out of Heidelberg, Germany. As of Jul 2017, NGN Capital has invested in 29 companies. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series C round of Exosome Diagnostics Overall, NGN Capital portfolio has seen 3 IPOs and 17 acquisitions including key companies like Horizon Therapeutics, Exosome Diagnostics and EKOS Corporation. A lot of funds co-invest with NGN Capital, with names like EGS Healthcare Capital Partners sharing a substantial percentage of its portfolio. NGN Capital has team of 7 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
NGN Capital's List of Top Investments
NGN Capital has a portfolio of 29 companies. Their most notable investments are in Jerini and BeneChill.Their portfolio spans across United States, Germany, Ireland and 3 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 2 other sectors, across stages such as Series B, Series A and 3 more. Here is the list of top investments by NGN Capital:Developer of drugs for treating rare and autoimmune diseases. The lead candidates of the company are UPLIZNA fucosylated IgG 1 kappa (IgG1κ) monoclonal antibodies for myasthenia gravis, HZN-825 for idiopathic pulmonary fibrosis, and HZN-4920 for focal segmental glomerulosclerosis as well as kidney transplant rejection, rheumatoid arthritis, and Sjogren’s syndrome.
Key facts about Horizon Therapeutics
- Founded Year: 2008
- Location: Dublin (Ireland)
- Annual Revenue: $1B+ as on Dec 31, 2022
- Stage: Acquired
- Total Funding till date: $61.8M
- Employee Count: 2,716 as on May 31, 2026
- Investors: Atlas Venture, Avoro Capital and 4 Others
- Latest Funding Round: Post IPO, Oct 2014, $*****
- Highlight: Acquired
Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring. The company's ExoDx Prostate test extract exosomes that contain disease-specific nucleic acids shed by solid tumors into bodily fluids and detect key genes and gene mutations associated with prostate cancer.
Key facts about Exosome Diagnostics
- Founded Year: 2008
- Location: Boston (United States)
- Stage: Acquired
- Total Funding till date: $119M
- Employee Count: 318 as on Jun 30, 2026
- Investors: b2venture, CD-Venture and 7 Others
- Latest Funding Round: Series C, Jul 05, 2017, $*****
- Highlight: Acquired
3. Cerapedics
Cerapedics is an orthobiologics company developing and commercializing its proprietary synthetic small peptide technology platform. i FACTOR Peptide Enhanced Bone Graft is a biologic bone graft that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. FDAs IDE trial was conducted for i FACTOR in which the product met all the four pre specified primary endpoints investigated in the study.
Key facts about Cerapedics
- Founded Year: 1996
- Location: Westminster (United States)
- Stage: Series D
- Total Funding till date: $88.5M
- Employee Count: 195 as on Aug 31, 2026
- Investors: MedImmune Ventures, Oxford Finance and 5 Others
- Latest Funding Round: Series D, Jul 13, 2018, $*****
- Highlight: Editors' Pick
Developer of a device for thrombolysis to treat pulmonary embolism. The EkoSonic Endovascular System is used in dissolving clots with its first generation of ultrasound thrombolytic technology. The acoustic energy from the device conditions clots by thinning fibrin, increasing porosity, and creating a pressure gradient that transports clot-dissolving drug deep inside the occluding thrombus. The company's products are used in the treatment of Deep Vein Thrombosis, Pulmonary embolism, and Peripheral arterial occlusion.
Key facts about EKOS Corporation
- Founded Year: 1995
- Location: Bothell (United States)
- Stage: Acquired
- Total Funding till date: $58.8M
- Employee Count: 64 as on May 31, 2026
- Investors: Trellis Partners, Hercules Capital and 17 Others
- Latest Funding Round: Series D, Jan 28, 2011, $*****
- Highlight: Acquired
5. Jerini
Jerini was a late stage biotechnology firm developing Bradykinin hormone inhibitors. Firazyr (icatibant) was a late-stage orphan drug for hereditary angiodema-a rare genetic disease. Jerini was listed on the Frankfurt stock exchange in 2005 and in 2008 it was acquired by Shire Plc for the molcule Firazyr. The drug received FDA approval on August 25, 2011. The R&D assets of Jerini were bought by 3B Pharma in 2009.
Key facts about Jerini
- Founded Year: 1994
- Location: Berlin (Germany)
- Stage: Acquired
- Total Funding till date: $76.2M
- Investors: Life Sciences Partners, EQT and 11 Others
- Latest Funding Round: Series B, Feb 15, 2005, $*****
- Highlight: Acquired
NGN Capital's Investments by Stage
NGN Capital has made 6 investments in Series B stage with an average round size of $23.2M, 5 investments in Series A stage with an average round size of $24.1M, 4 investments in Series C stage with an average round size of $31.1M, 2 investments in Series D stage with an average round size of $30.2M and 1 investment in Conventional Debt stage with an average round size of $32M.Stage of entry | No. of Investments |
|---|---|
Series B | 6 |
Series A | 5 |
Series C | 4 |
Series D | 2 |
Conventional Debt | 1 |
Note: We have considered here, only first round of investments
NGN Capital's Investments by Sector
NGN Capital has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, HealthTech and Internet of Things - Industry Applications. Notably, it has invested in 26 Tech companies, 19 Enterprise (B2B) companies, 12 Software companies and at least 6 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 16 |
Enterprise Applications | 3 |
High Tech | 3 |
HealthTech | 2 |
Internet of Things - Industry Applications | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
NGN Capital's Investments by Geography
NGN Capital has made most investments in United States (13), followed by Germany where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 13 |
Germany | 2 |
Switzerland | 2 |
Israel | 1 |
Note: We have considered here, only first round of investments
NGN Capital's recent investments
NGN Capital has not made any investment in 2026 so far.Here are the most recent investments by NGN Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 05, 2017 | United States | Series C | 4514 | [+5] | |
Sep 15, 2015 | United States | Series B | 4365 | [+2] | |
Mar 12, 2014 | United States | Series B | 7852 | [+2] | |
Nov 27, 2012 | Switzerland | Series C | 8878 | [+5] | |
Nov 27, 2012 | United States | Series C | 8027 | [+1] |
IPOs and Publicly Listed companies in NGN Capital's Portfolio
3 of NGN Capital's portfolio companies have become public. Noxxon Pharma got listed on the Euronext Exchange (Euronext), in Sep 2016 at marketcap of $49.1M and Resverlogix got listed on the Toronto Stock Exchange (TSX).Here are NGN Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 30, 2016 | May 27, 2010 | Series D | 8667 | |
Jan 17, 2005 | - | - | 3800 | |
- | - | - | 9252 |
Acquired companies in NGN Capital's Portfolio
17 companies from NGN Capital's portfolio have been acquired. The most recent acquisition was Horizon Therapeutics in Dec 2022 by Amgen for $*****.Here are NGN Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 12, 2022 | - | - | 4766 | |
Jun 25, 2018 | May 12, 2010 | Series A | 2229 | |
Nov 28, 2016 | Feb 02, 2010 | Series B | 9918 | |
Oct 13, 2016 | Jul 27, 2009 | Series C | 1885 | |
Oct 06, 2015 | Sep 10, 2008 | Series C | 9182 |
Team profile of NGN Capital
NGN Capital has a team of 7 members including 4 Partners, 1 Venture Partner and 1 Principal located in United States and Germany. NGN Capital's team does not sit on the board of any company as of now.Here is a list of all team members in NGN Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Lake Worth | - | ||
Partner | Frankfurt Am Main | - | ||
Partner | New York City | - | ||
Partner | Germany | - | - | |
Venture Partner | Walnut Creek | - | - | |
Principal | Stamford | - | - |
Co-investors of NGN Capital
Over the past 21 years, 109 investors have co-invested in NGN Capital's portfolio companies. This includes funds and angels.
- Invested before NGN Capital: Edmond de Rothschild, Orbimed and 23 others have invested in rounds before NGN Capital. There are 2 companies where Edmond de Rothschild has invested before NGN Capital and 1 company where Orbimed has invested before NGN Capital.
- Top Co-investors of NGN Capital: 38 investors entered a company along with NGN Capital. These include investors like EGS Healthcare Capital Partners (2 companies).
- Invested after NGN Capital: A total of 46 investors have invested in NGN Capital's portfolio after their investments. Top Investors include CD-Venture (2 companies), Oxford Finance (2 companies) and Qiagen (1 company).
Recent News related to NGN Capital
•
Massachusetts' Exosome Diagnostics Snags $30 Million | BioSpaceBioSpace•Jul 24, 2017•Exosome Diagnostics, Forbion, Tiger Advisors, Blue Ridge Capital and 4 others
•
Cerapedics Closes $15 Million Series B Financing | Business WireBusiness Wire•Apr 06, 2009•Cerapedics, NGN Capital, Orbimed
•
•
Vivaldi Biosciences Enters Into Agreements for $23 Million in Series A FinancingBusiness Wire•Jan 08, 2009•Vivaldi Biosciences, Bay City Capital, NGN Capital, Alexandria and 1 other
•
Nitec Pharma AG secures funding of CHF 24M | FierceBiotechFierce Biotech•Sep 30, 2008•Nitec Pharma, TVM Capital, Atlas Venture, NGN Capital and 2 others
•
Tigris Pharma Raises $16 Million - PE HubPE Hub•Jan 16, 2007•Tigris Pharmaceuticals, Wexford Capital, Riverbank Capital Securities, NGN Capital
•
•
•
